(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.26%) $2.14
(0.02%) $2 310.10
(-0.52%) $26.69
(0.28%) $965.30
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
0.71% € 31.14
Live Chart Being Loaded With Signals
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally...
Stats | |
---|---|
Volumen de hoy | 48 516.00 |
Volumen promedio | 39 140.00 |
Capitalización de mercado | 555.51M |
EPS | €0 ( 2024-04-24 ) |
Próxima fecha de ganancias | ( €0 ) 2024-07-25 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 283.09 |
ATR14 | €0.0730 (0.23%) |
Volumen Correlación
Pharma Mar, S.A. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pharma Mar, S.A. Correlación - Moneda/Commodity
Pharma Mar, S.A. Finanzas
Annual | 2023 |
Ingresos: | €158.15M |
Beneficio Bruto: | €144.86M (91.60 %) |
EPS: | €0.0635 |
FY | 2023 |
Ingresos: | €158.15M |
Beneficio Bruto: | €144.86M (91.60 %) |
EPS: | €0.0635 |
FY | 2022 |
Ingresos: | €196.34M |
Beneficio Bruto: | €182.70M (93.05 %) |
EPS: | €2.73 |
FY | 2021 |
Ingresos: | €229.83M |
Beneficio Bruto: | €213.39M (92.85 %) |
EPS: | €5.14 |
Financial Reports:
No articles found.
Pharma Mar, S.A.
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico